c-MET (D1228H)
Sign in to save this workspaceMET · Variant type: point · HGVS: p.D1228H
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 92.8% | 7.3% | 88.97 |
| 2 | Cabozantinib | 85.9% | 14.1% | 92.73 |
| 3 | Tivozanib | 82.9% | 17.1% | 92.42 |
| 4 | Pacritinib | 76.5% | 23.5% | 88.64 |
| 5 | Crizotinib | 75.0% | 24.9% | 91.39 |
| 6 | Defactinib | 71.9% | 28.1% | 92.68 |
| 7 | Neratinib | 66.0% | 34.0% | 93.18 |
| 8 | Repotrectinib | 63.1% | 36.9% | 84.21 |
| 9 | Selpercatinib | 60.5% | 39.5% | 96.72 |
| 10 | Fostamatinib | 58.4% | 41.6% | 96.74 |
| 11 | Imatinib | 47.8% | 52.2% | 99.00 |
| 12 | Osimertinib | 47.5% | 52.5% | 97.24 |
| 13 | Tepotinib | 36.8% | 63.2% | 99.75 |
| 14 | Canertinib | 36.6% | 63.4% | 96.49 |
| 15 | Capmatinib | 33.3% | 66.7% | 99.75 |
| 16 | Fedratinib | 33.3% | 66.7% | 96.21 |
| 17 | Sunitinib | 29.6% | 70.4% | 91.73 |
| 18 | Lenvatinib | 28.0% | 72.0% | 97.74 |
| 19 | Abemaciclib | 27.5% | 72.5% | 91.48 |
| 20 | Trametinib | 23.9% | 76.1% | 99.50 |
| 21 | Ibrutinib | 23.8% | 76.2% | 94.74 |
| 22 | Brigatinib | 23.5% | 76.5% | 82.96 |
| 23 | Ribociclib | 22.0% | 78.0% | 99.25 |
| 24 | Vemurafenib | 20.1% | 79.9% | 96.49 |
| 25 | Entrectinib | 19.3% | 80.7% | 93.69 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 92.8% | — | — |
| Cabozantinib | 85.9% | — | — |
| Tivozanib | 82.9% | — | — |
| Pacritinib | 76.5% | — | — |
| Crizotinib | 75.0% | — | — |
| Defactinib | 71.9% | — | — |
| Neratinib | 66.0% | — | — |
| Repotrectinib | 63.1% | — | — |
| Selpercatinib | 60.5% | — | — |
| Fostamatinib | 58.4% | — | — |
| Imatinib | 47.8% | — | — |
| Osimertinib | 47.5% | — | — |
| Tepotinib | 36.8% | — | — |
| Canertinib | 36.6% | — | — |
| Capmatinib | 33.3% | — | — |
| Fedratinib | 33.3% | — | — |
| Sunitinib | 29.6% | — | — |
| Lenvatinib | 28.0% | — | — |
| Abemaciclib | 27.5% | — | — |
| Trametinib | 23.9% | — | — |
| Ibrutinib | 23.8% | — | — |
| Brigatinib | 23.5% | — | — |
| Ribociclib | 22.0% | — | — |
| Vemurafenib | 20.1% | — | — |
| Entrectinib | 19.3% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.3ms